Effects of High-and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

被引：0
|
作者：
Tran, Jonathan Q. [1 ]
Hartung, Jeffrey P. [2 ]
Tompkins, Cindy-ann [3 ]
Frohna, Paul A. [3 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Receptos Inc, San Diego, CA USA
[3] Receptos Inc, Summit, NJ USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
10.14309/00000434-201610001-00650
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
650
引用
下载
收藏
页码：S298 / S298
页数：1
相关论文
共 50 条
  • [1] Effects of high- and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator
    Tran, J. Q.
    Hartung, J. P.
    Tompkins, C. -A.
    Frohna, P. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 374 - 375
  • [2] Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-I-Phosphate Receptor Modulator
    Tran, Jonathan Q.
    Hartung, Jeffrey P.
    Tompkins, Cindy-Ann
    Frohna, Paul A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 634 - 640
  • [3] Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator
    Surapaneni, Sekhar
    Yerramilli, Usha
    Bai, April
    Dalvie, Deepak
    Brooks, Jennifer
    Wang, Xiaomin
    Selkirk, Julie, V
    Yan, Yingzhuo Grace
    Zhang, Peijin
    Hargreaves, Richard
    Kumar, Gondi
    Palmisano, Maria
    Tran, Jonathan Q.
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (05) : 405 - 419
  • [4] Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor agonist
    Tran, J. Q.
    Zhang, P.
    Surapaneni, S.
    Selkirk, J.
    Yan, G.
    Palmisano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 524 - 525
  • [5] Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis
    Choi, David
    Stewart, Alyssa P.
    Bhat, Shubha
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (05) : 592 - 599
  • [6] Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys
    Inaba, Shin-Ichi
    Ikeda, Tomoko
    Goto, Maki
    Tanaka, Hisako
    Takahashi, Makoto
    Iwabuchi, Haruo
    Izumi, Takashi
    XENOBIOTICA, 2015, 45 (12) : 1063 - 1080
  • [7] Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5
    Selkirk, Julie V.
    Bortolato, Andrea
    Yan, Yingzhuo Grace
    Ching, Nathan
    Hargreaves, Richard
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Sphingosine kinase 1/sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 pathway: A novel target of geniposide to inhibit angiogenesis
    Sun, Minghui
    Deng, Ran
    Wang, Yan
    Wu, Hong
    Zhang, Zhengrong
    Bu, Yanhong
    Zhang, Heng
    LIFE SCIENCES, 2020, 256
  • [9] An oral sphingosine 1-phosphate receptor modulator for the treatment of multiple sclerosis
    不详
    FORMULARY, 2010, 45 (11) : 335 - 335
  • [10] Fingolimod: A novel therapy, a sphingosine 1-phosphate receptor modulator for the treatment of relapsing multiple sclerosis
    Jose de Jesus, Flores-Rivera
    REVISTA MEXICANA DE NEUROCIENCIA, 2011, 12 (05): : 250 - 261
12345